Log In
BCIQ
Print this Print this
 

ABX464

  Manage Alerts
Collapse Summary General Information
Company Abivax S.A.S.
DescriptionSmall molecule inhibitor of viral replication that acts by preventing rev-mediated export of unspliced HIV-1 transcripts to the cytoplasm and by interacting with the cap binding complex (CBC)
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV infection
Regulatory Designation
PartnerCentre National de la Recherche Scientifique (CNRS);
Theradiag S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$20.4M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/13/2016

$20.4M

Undisclosed

0

Get a free BioCentury trial today